|
COVID-19 Vaccine Data
In Michigan, we have distributed 1,047,275 vaccines to state partners for administration. We have reported administering 760,066 first and second doses of vaccines for priority groups (as of 1/25/21). In addition, 430,200 has been allocated to the federal program for administration in long-term care facilities for a total of 1,477,475 vaccines distributed in the state.
This data is current data as of January 26, 2021 unless otherwise noted.
|
|
COVID-19 Vaccination Strategy
Michigan's Interim COVID-19 Vaccination Strategy was unveiled today during the first Protect Michigan Commission meeting. The presentation outlines the state's guiding principles, goals, vaccine allocation strategy, interim vaccination schedule, and five overall strategies that align with President Biden's new national strategy.
Guiding Principles
- All Michiganders have equitable access to vaccines.
- Vaccine planning and distribution is inclusive.
- Communications are transparent, accurate, and frequent to build public trust.
- Data is used to promote equity, track progress, and guide decision-making.
- Resource stewardship, efficiency, and continuous quality improvement drive strategic implementation.
Goals
|
|
Preventing Vaccine Waste
Minimizing vaccine waste is critical to meeting the goal of vaccinating 70% of Michiganders by the end of the year. When preparing for clinics or mass vaccination sites, protect the vaccine supply:
- Pull only the amount of vaccine necessary for the number of people scheduled for the clinic.
- Create a list of people to have as backup in case someone does not show up, or an extra dose is able to be pulled from a vial. Have the list on site at every vaccine clinic.
It is not recommended to predraw vaccine, if vaccine must be predrawn for a clinic or mass vaccination site:
-
Only predraw vaccine after arriving at the clinic or site, not prior to transport.
-
Only one vial should be predrawn at a time by each health care professional.
-
The vaccine should be drawn up and administered by the same health care professional.
-
Monitor patient flow to avoid drawing up unnecessary doses.
-
Never transfer predrawn vaccine back into a vial for storage.
-
All doses must be used within 6 hours after puncturing the vial (Moderna) or reconstituting vaccine (Pfizer).
Additional Resources
CDC Vaccine Storage and Handling Toolkit
CDC Information on Pfizer and Moderna Vaccine
|
|
Report indicates anaphylaxis events after administration of Moderna COVID-19 vaccine to be a rare event
Early safety monitoring through the Vaccine Adverse Event Reporting System has detected 10 cases of anaphylaxis after administration of 4,041,386 first doses of Moderna COVID-19 vaccine.
- In nine cases, onset occurred within 15 minutes of vaccination.
- Nine of those patients had a history of allergies or allergic reactions, including five with previous anaphylaxis events.
- All ten patients received epinephrine as part of initial emergency treatment. Six patients were hospitalized. No deaths from anaphylaxis were reported.
Based on this early monitoring, anaphylaxis after receipt of Moderna COVID-19 Vaccine appears to be a rare event. Estimated initial rate is 2.5 per million first doses of the Moderna COVID-19 Vaccine. A previous analysis of the Pfizer-BioNTech COVID-19 Vaccine estimated an initial rate of 11.1 cases per million first doses of the Pfizer-BioNTech Vaccine.
Read the full report.
|
|
|
|
